Dr. Talha Badar, M.D
What this data tells you about Dr. Badar
Dr. Talha Badar is a hematology & oncology in Jacksonville, FL, with 12 years in practice. Based on federal Medicare data, Dr. Badar performed 68,706 Medicare services across 2,423 unique beneficiaries.
Between the years covered by Open Payments, Dr. Badar received a total of $18,297 from 10 pharmaceutical and/or device companies across 25 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Badar is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 12,000 | $41 | $195 |
| Nivolumab injection (Opdivo) | 9,320 | $24 | $114 |
| Anti-nausea injection (fosaprepitant) | 7,950 | $0 | $1 |
| Darbepoetin injection (Aranesp) for anemia | 6,775 | $2 | $11 |
| Daratumumab injection (Darzalex) | 6,120 | $38 | $189 |
| Iron infusion (Feraheme) | 6,120 | $0 | $2 |
| Paclitaxel chemotherapy injection | 4,572 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 2,700 | $18 | $90 |
| Dexamethasone injection (steroid) | 1,830 | $0 | $3 |
| Anti-nausea injection (ondansetron/Zofran) | 1,552 | $0 | $5 |
| Immune globulin infusion (Gammagard) | 1,480 | $36 | $137 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1,330 | $23 | $182 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,020 | $22 | $192 |
| Injection, atropine sulfate, 0.01 mg | 805 | $0 | $1 |
| Injection, bortezomib, 0.1 mg | 630 | $3 | $9 |
| Injection of additional new drug or substance into vein | 459 | $12 | $216 |
| Office visit, established patient (30-39 min) | 401 | $94 | $450 |
| Injection, irinotecan, 20 mg | 341 | $2 | $25 |
| Anti-nausea injection (Aloxi/palonosetron) | 330 | $1 | $8 |
| Administration of chemotherapy into vein, 1 hour or less | 296 | $100 | $869 |
| Injection, carboplatin, 50 mg | 264 | $2 | $29 |
| Collection of blood sample from implanted device | 193 | $20 | $135 |
| Injection, fluorouracil, 500 mg | 186 | $2 | $28 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 179 | $3 | $36 |
| Hospital follow-up visit, high complexity | 156 | $96 | $452 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 136 | $133 | $490 |
| Injection, leucovorin calcium, per 50 mg | 131 | $3 | $23 |
| Drug injection, under skin or into muscle | 127 | $11 | $102 |
| Injection, potassium chloride, per 2 meq | 120 | $0 | $17 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 100 | $22 | $233 |
| Infusion, normal saline solution , 1000 cc | 98 | $2 | $82 |
| Administration of additional new drug or substance into vein, 1 hour or less | 92 | $48 | $446 |
| Administration of chemotherapy into vein, each additional hour | 88 | $22 | $212 |
| Infusion into a vein for hydration, each additional hour | 84 | $10 | $114 |
| Injection, magnesium sulfate, per 500 mg | 76 | $1 | $17 |
| Injection, diphenhydramine hcl, up to 50 mg | 66 | $1 | $38 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 63 | $55 | $352 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 63 | $26 | $200 |
| New patient office visit, complex (60-74 min) | 63 | $162 | $891 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 62 | $49 | $426 |
| Injection, zoledronic acid, 1 mg | 55 | $6 | $52 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 53 | $16 | $154 |
| Infusion into a vein for hydration, 31-60 minutes | 38 | $25 | $345 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 33 | $15 | $143 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 31 | $133 | $993 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 31 | $1 | $80 |
| Office visit, established patient, complex (40-54 min) | 22 | $143 | $604 |
| Hospital discharge management, 30+ min | 20 | $92 | $487 |
| Injection of drug or substance into vein | 18 | $27 | $600 |
| Administration of additional new drug or substance into vein using push technique | 15 | $43 | $370 |
| Initial hospital admission, moderate complexity | 12 | $106 | $630 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (49%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Badar is a mixed practice specialist, with above-average Medicare volume (top 12% in FL), and consulting-driven industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Badar experienced with pembrolizumab injection (keytruda)?
Does Dr. Badar receive payments from pharmaceutical companies?
How do Dr. Badar's costs compare to other hematology & oncologys in Jacksonville?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology